The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride), for the treatment of schizophrenia, a chronic mental health disorder. Developed by Karuna Therapeutics and now owned by Bristol Myers Squibb, Cobenfy works by targeting cholinergic receptors unlike traditional antipsychotic medications that target dopamine receptors. This marks a significant departure from the conventional approach to schizophrenia treatment, according ...

Researchers have shown that childhood sexual, physical and emotional abuse are associated with severe hallucinations in schizophrenia. The joint study by several research institutes found that hallucinations in schizophrenia were linked with childhood trauma, said Sarah Bendall, the lead author. The study has analyzed 29 studies on childhood trauma and psychotic symptoms and found that childhood sexual abuse is often ...